PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
AADI vs. CPRX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between AADI and CPRX is 0.20, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

AADI vs. CPRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Aadi Bioscience, Inc. (AADI) and Catalyst Pharmaceuticals, Inc. (CPRX). The values are adjusted to include any dividend payments, if applicable.

0.00%200.00%400.00%600.00%800.00%AugustSeptemberOctoberNovemberDecember2025
-96.69%
688.24%
AADI
CPRX

Key characteristics

Sharpe Ratio

AADI:

1.05

CPRX:

1.37

Sortino Ratio

AADI:

2.01

CPRX:

2.25

Omega Ratio

AADI:

1.26

CPRX:

1.26

Calmar Ratio

AADI:

0.89

CPRX:

1.50

Martin Ratio

AADI:

3.84

CPRX:

7.69

Ulcer Index

AADI:

22.75%

CPRX:

7.31%

Daily Std Dev

AADI:

83.24%

CPRX:

41.20%

Max Drawdown

AADI:

-98.67%

CPRX:

-94.25%

Current Drawdown

AADI:

-96.99%

CPRX:

-4.81%

Fundamentals

Market Cap

AADI:

$73.55M

CPRX:

$2.72B

EPS

AADI:

-$2.28

CPRX:

$1.19

Total Revenue (TTM)

AADI:

$18.74M

CPRX:

$349.91M

Gross Profit (TTM)

AADI:

$16.51M

CPRX:

$293.37M

EBITDA (TTM)

AADI:

-$45.12M

CPRX:

$141.71M

Returns By Period

In the year-to-date period, AADI achieves a -5.55% return, which is significantly lower than CPRX's 9.15% return.


AADI

YTD

-5.55%

1M

28.45%

6M

108.39%

1Y

82.82%

5Y*

-20.27%

10Y*

N/A

CPRX

YTD

9.15%

1M

6.15%

6M

34.47%

1Y

56.46%

5Y*

40.62%

10Y*

23.38%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

AADI vs. CPRX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AADI
The Risk-Adjusted Performance Rank of AADI is 7878
Overall Rank
The Sharpe Ratio Rank of AADI is 7979
Sharpe Ratio Rank
The Sortino Ratio Rank of AADI is 8080
Sortino Ratio Rank
The Omega Ratio Rank of AADI is 7979
Omega Ratio Rank
The Calmar Ratio Rank of AADI is 7777
Calmar Ratio Rank
The Martin Ratio Rank of AADI is 7676
Martin Ratio Rank

CPRX
The Risk-Adjusted Performance Rank of CPRX is 8484
Overall Rank
The Sharpe Ratio Rank of CPRX is 8585
Sharpe Ratio Rank
The Sortino Ratio Rank of CPRX is 8484
Sortino Ratio Rank
The Omega Ratio Rank of CPRX is 7979
Omega Ratio Rank
The Calmar Ratio Rank of CPRX is 8686
Calmar Ratio Rank
The Martin Ratio Rank of CPRX is 8888
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

AADI vs. CPRX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Aadi Bioscience, Inc. (AADI) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for AADI, currently valued at 1.05, compared to the broader market-2.000.002.004.001.051.37
The chart of Sortino ratio for AADI, currently valued at 2.01, compared to the broader market-4.00-2.000.002.004.002.012.25
The chart of Omega ratio for AADI, currently valued at 1.26, compared to the broader market0.501.001.502.001.261.26
The chart of Calmar ratio for AADI, currently valued at 0.89, compared to the broader market0.002.004.006.000.891.50
The chart of Martin ratio for AADI, currently valued at 3.84, compared to the broader market-10.000.0010.0020.0030.003.847.69
AADI
CPRX

The current AADI Sharpe Ratio is 1.05, which is comparable to the CPRX Sharpe Ratio of 1.37. The chart below compares the historical Sharpe Ratios of AADI and CPRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.502.002.50AugustSeptemberOctoberNovemberDecember2025
1.05
1.37
AADI
CPRX

Dividends

AADI vs. CPRX - Dividend Comparison

Neither AADI nor CPRX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

AADI vs. CPRX - Drawdown Comparison

The maximum AADI drawdown since its inception was -98.67%, roughly equal to the maximum CPRX drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for AADI and CPRX. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-96.99%
-4.81%
AADI
CPRX

Volatility

AADI vs. CPRX - Volatility Comparison

Aadi Bioscience, Inc. (AADI) has a higher volatility of 50.31% compared to Catalyst Pharmaceuticals, Inc. (CPRX) at 19.25%. This indicates that AADI's price experiences larger fluctuations and is considered to be riskier than CPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%AugustSeptemberOctoberNovemberDecember2025
50.31%
19.25%
AADI
CPRX

Financials

AADI vs. CPRX - Financials Comparison

This section allows you to compare key financial metrics between Aadi Bioscience, Inc. and Catalyst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab